4-Hydroxytolbutamide (Hydroxytolbutamide) is a metabolite of Tolbutamide. 4-Hydroxytolbutamide is metabolized by CYP2C8 and CYP2C9. Tolbutamide is a first generation potassium channel blocker and a sulfonylurea oral antidiabetic.

Dofetilide N-oxide (UK-116856) is a metabolite of Dofetilide. Dofetilide is a class III antiarrhythmic agent that blocks potassium channels.

A-887826 is a potent, selective, oral bioavailable and voltage-dependent Na(v)1.8 sodium channel blocker with an IC50 of 11 nM . A-887826 attenuates neuropathic tactile allodynia in vivo.

α5IA is a selective inverse agonist for Α5 subtype of GABAA receptor with a higher intrinsic activity at the A5 subtype than other drugs.

ZK 200775 is a competitive GluR (AMPA)/kainate antagonist.

Zatebradine(UL-FS49) is a potent HCN channels antagonist, which decreased the heartbeat in a reversible manner; 92% inhibition of the hHCN1-mediated current at 10 uM.

Zatebradine hydrochloride is a bradycardic agent that creates use-dependent inhibition of hyperpolarization-activated current (If) in sinoatrial node cells (EC50 = 480 nM) and Purkinje fibres.

Vilazodone (EMD 68843) is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evaluation.

Vigabatrin Hcl(γ-Vinyl-GABA; Sabril) is a structural analog of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) that irreversibly inhibits the catabolism of GABA by GABA transaminase.

Transcrocetinate disodium, extracted from saffron (Crocus sativus L.), acts as an NMDA receptor antagonist with high affinity.

Tolbutamide is a first generation potassium channel blocker, sulfonylurea oral hypoglycemic drug.

Tolazamide is a first generation sulfonylurea that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (KIR6.2; IC50 = 4.2 µM in HEK293 cells transfected with the human receptor).

Tofogliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2).

The first small-molecule inhibitor of renal outer medullary potassium channel (ROMK, Kir1.1) and Kir7.1 with IC50 of 294 nM for ROMK.

Tebanicline hydrochloride (ABT594 hydrochloride) is a nAChR modulator with potent, orally effective analgesic activity. It inhibits the binding of cytisine to α4β2 neuronal nAChRs with a Ki of 37 pM.

SYM2206 is a novel, potent, non-competitive AMPA receptor antagonist (IC50 = 2.8 μM ).

SRI-31142 (SRI31142) is a novel potent, putative allosteric dopamine transporter (DAT) inhibitor with Ki of 1.9 nM..

Sodium Channel inhibitor1, one of 3-Oxoisoindoline-1-carboxamides, is a novel and selective voltage-gated sodium channel for pain treatment.

SN 2 is a novel and potent small molecule activator of TRPML3 with EC50 of 1.13 uM.

Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.

Selective AMPA receptor antagonist (Ki values are 84, 2200 and > 37000 nM For AMPA, kainate and NMDA receptors respectively). Neuroprotective.

SDZ 220-581 is a potent, competitive antagonist at the NMDA glutamate receptor subtype(pKi= 7.7).

SDZ 220-581 Hcl is a potent, competitive antagonist at the NMDA glutamate receptor subtype(pKi= 7.7).

S44819 (S 44819, Egis-13529) is a novel potent, competitive, selective antagonist of the α5-GABAAR with Kd of 221 nM, IC50 of 585 nM (α5β2γ2).

RPR260243 was the first reported hERG channel activator.